Mutations that alter signaling of RAS/MAPK-family proteins give rise to a group 61 of Mendelian diseases known as RASopathies, but the matrix of genotype-phenotype 62 relationships is still incomplete, in part because there are many RAS-related proteins, 63 and in part because the phenotypic consequences may be variable and/or pleiotropic.
Introduction
Results 133 This study originated as a collaboration facilitated by GeneMatcher through shared 134 interests in RALA as a result of observations from exome sequencing (ES) or genome 135 sequencing (GS) as part of DD/ID-related clinical or research testing. In the Methods 136 and Appendix S1, we describe the research sites that identified one or more affected 137 probands reported in this study, the methods used for sequencing and analysis, and 138 related details. In total, we identified RALA mutations in eleven affected probands from 139 ten unrelated families. These variants were identified from a combined cohort of over 140 16,000 probands sequenced by six groups who independently submitted RALA to 141 GeneMatcher (Table 1, Appendix S1). Figure S5 ). Variation at all 197 five of these residues is thus predicted to alter GTP/GDP binding. This conclusion is consistent 198 with the high degree of conservation at these residues throughout evolution in RALA Enrichment and clustering of missense variation 211 We next assessed whether the de novo variants in our cohort were enriched compared 212 to that which would be expected in the absence of a disease association. Eight unrelated 213 individuals were drawn from cohorts of at least 400 proband-parent trios, collectively spanning 214 16,086 probands (Appendix S1). When comparing the frequency of observed de novo variation 215 to the expected background frequency of de novo missense or loss-of-function variation in 216 RALA (6.16 x 10 -6 per chromosome) [17], we find a highly significant enrichment for de novo 217 variants in affected probands (8 observed de novo variants in 32172 screened alleles vs. 0.198 218 expected, Exact Binomial test p=4.93 x 10 -11 ). We note that this p-value is likely conservative, as 219 it results from comparison of the observed rate to the expected frequency of de novo variation 220 over the entire gene. However, six of the nine de novo alleles affect only two codons, and all 221 observed de novo variants are within the GTP-interacting space of 24 residues (11.7% of the 222 206-aa protein, Figure 2A ). This clustering likely reflects a mechanism of disease that depends 223 specifically on alterations to GTP/GDP binding and, subsequently, RALA signaling.
224
Population genetic data also support pathogenicity of these variants. RALA has a pLI 225 score of 0.95 in ExAC [10], suggesting that it is intolerant to loss-of-function variation. While
226
RALA has an RVIS score rank [18] of 50.45%, it also has an observed/expected ratio percentile of 227 0.92%, a score that has been suggested to be more accurate for small proteins wherein that was not observed in probands but which carries a missense substitution, G23D, 261 homologous to the G12D KRAS or HRAS variant commonly observed in tumor tissue ( Figure 3A) .
262
downstream effects [20, 21] , we also assessed binding of these mutants to a RALA effector 264 protein using an ELISA-based method (see Methods). In this assay, recombinant G23D RALA 265 protein exhibited approximately two-fold increased binding (p < 0.0001, Figure 3B ), as 266 anticipated for a constitutively active gain-of-function alteration [20, 25] . V25L, V25M, D130G 267 and R176X each showed a roughly 2-5-fold reduction in effector binding compared to wild-type 268 (each p < 0.0001, Figure 3B ). In contrast, the S157A mutant exhibited increased binding 269 compared to wild-type, suggesting that it may act in a constitutively-active manner similar to 270 G23D (p < 0.0001, Figure 3B ). We note that while there is some variation among mutants in the 271 efficiency of protein production and purification (Methods, Supplemental Figure S9 ), whether 272 or not one normalizes to relative band intensity from Western blots of purified protein does not 273 qualitatively affect these conclusions (Supplemental Figure S10 ).
275
Other candidate variants in probands with RALA variants 276 In this and other cases of rare disease sequencing, it is important to consider other 277 variation in any given patient that may be pathogenic. In six of the eleven cases presented here,
278
the RALA variant was found to be the only plausible candidate. In five cases, other variants 279 were discovered that were also initially considered as potential disease-causing mutations. Proband 11 carries a nonsense variant, R176X, which is unusual given the apparent 296 specificity for the GTP/GDP-binding region of RALA observed in the other cases in our cohort.
297
Clinically, we consider the R176X to be a variant of uncertain significance for several reasons.
298
The R176X allele has been observed twice in the Bravo genome database, and parental DNA for 299 this proband was not available, so we do not know whether the variant is de novo or inherited.
300
In addition, the proband has microcephaly and more profound delays than others in the cohort, 301 and also has large regions of homozygosity consistent with parental consanguinity. These 302 regions of homozygosity suggests an additional and/or more complex molecular pathogenesis. We thank all families involved in the study. This work was supported by the following grants: representation. V25 is in yellow, K128 in blue, D130 in red, S157 in magenta, and A158 in black.
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